Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0ASYKZ)
| ADC Name |
Izeltabart tapatansine
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
izeltabart tapatansine; IMGC936; IMGC936-0901
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen (Top20 MNC) (Originator);MacroGenics (Originator) (No Rights)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Izeltabart
|
Antibody Info | ||||
| Antigen Name |
Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9)
|
Antigen Info | ||||
| Payload Name |
DM21-C
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Ala-Ala-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
tapatansine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
|||||
| Colorectal cancer |
1 Trials
|
|||||
| Pancreatic cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Breast cancer |
1 Trials
|